Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-1.60% $14.72
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 913.07 mill |
EPS: | 0.810 |
P/E: | 18.17 |
Earnings Date: | Mar 13, 2024 |
SharesOutstanding: | 62.03 mill |
Avg Daily Volume: | 1.404 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 18.17 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
3.09x |
Company: PE 18.17 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.0136 (-100.09%) $-14.73 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 13.24 - 16.21 ( +/- 10.09%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-06 | Peters Jeffrey Stuart | Sell | 8 750 | Employee stock option (right to buy) |
2024-03-06 | Peters Jeffrey Stuart | Buy | 8 750 | Common Stock |
2024-03-06 | Peters Jeffrey Stuart | Buy | 10 875 | Common Stock |
2024-03-06 | Peters Jeffrey Stuart | Sell | 19 625 | Common Stock |
2024-03-06 | Peters Jeffrey Stuart | Sell | 10 875 | Employee stock option (right to buy) |
INSIDER POWER |
---|
48.22 |
Last 100 transactions |
Buy: 2 029 319 | Sell: 658 073 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $14.72 (-1.60% ) |
Volume | 0.771 mill |
Avg. Vol. | 1.404 mill |
% of Avg. Vol | 54.92 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $18.50 | N/A | Active |
---|
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.